NASDAQ:SLNO - Soleno Therapeutics Stock Price, Forecast & News

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. View Soleno Therapeutics' Earnings History.

Soleno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Soleno Therapeutics.

3 equities research analysts have issued 1-year price objectives for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect Soleno Therapeutics' stock price to reach $9.33 in the next year. This suggests a possible upside of 182.8% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.

Media stories about SLNO stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soleno Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Soleno Therapeutics.

Soleno Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 387,000 shares, an increase of 626.1% from the December 31st total of 53,300 shares. Based on an average trading volume of 244,600 shares, the short-interest ratio is currently 1.6 days. Approximately 1.4% of the shares of the company are sold short. View Soleno Therapeutics' Current Options Chain.

Some companies that are related to Soleno Therapeutics include AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Stereotaxis (STXS), Semler Scientific (SMLR), Zynex (ZYXI), Viewray (VRAY), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP), Second Sight Medical Products (EYES), electroCore (ECOR) and Fc Global Realty (FCRE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Opko Health (OPK), Molecular Templates (MTEM), Agile Therapeutics (AGRX), SCYNEXIS (SCYX), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Cidara Therapeutics (CDTX) and Novavax (NVAX).

Soleno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Lindbrook Capital LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Institutional Ownership Trends for Soleno Therapeutics.

SLNO stock was purchased by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SLNO stock can currently be purchased for approximately $3.30.

Soleno Therapeutics has a market capitalization of $147.37 million. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.

The official website for Soleno Therapeutics is http://www.soleno.life/.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]